Everolimus-eluting versus sirolimus-eluting stents : A meta-analysis of randomized trials

Circulation: Cardiovascular Interventions

Volumn 4, Issue 4, 2011, Pages 371-377

  De Waha, Antoinette ^a   Dibra, Alban ^a   Byrne, Robert A ^a   Ndrepepa, Gjin ^a   Mehilli, Julinda ^a   Fusaro, Massimiliano ^a   Laugwitz, Karl Ludwig ^a   Massberg, Steffen ^a   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiac death; Everolimus eluting stent; Sirolimus eluting stent; Stent thrombosis

Indexed keywords

CYPHER; EVEROLIMUS; RAPAMYCIN; UNCLASSIFIED DRUG;

CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; STENT THROMBOSIS;

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PROSTHESIS IMPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 80052144197     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.963256     Document Type: Review

References (27)

1. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030-1039. (Pubitemid 46376803)
2. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
3. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008. (Pubitemid 46376800)
4. Byrne RA, Sarafoff N, Kastrati A, Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf. 2009;32:749-770.
5. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-1510. (Pubitemid 46986103)
6. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Cardiovasc Interv. 2009;2:291-299.
7. Wijns W. First-generation drug-eluting stents ⋯ and beyond. Drug Saf. 2009;32:771-773.
8. Kukreja N, Onuma Y, Serruys PW. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices. 2009;6:219-229.
9. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxeleluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-209.
10. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Euro- Intervention. 2006;2:286-294.
11. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913. (Pubitemid 351574920)
12. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674.
13. Schömig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373-1380. (Pubitemid 47449734)
14. Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehilli M. Biodegradable polymer versus permanent polymer drugeluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: three-year outcomes from a randomized clinical trial. J Am Coll Cardiol. In press.
15. Jensen LO. SORT OUT 4: a prospective randomized trial of everolimuseluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at the Transcatheter Cardiovascular Therapeutics Meeting, Washington D.C., September 2010.
16. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010;363:2310-2319.
17. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, Park DW, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Lee BK, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Park WJ, Kim HS, Chae JK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Choi YJ, Cheong SS, Yang TH, Jang JS, Her SH, Park SJ. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus: results from ESSENCE-DIABETES trial. Circulation. In press.
18. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Chun DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS. Everolimus-eluting versus sirolimuseluting stents in patients undergoing percutaneous coronary Intervention: the EXCELLENT randomized trial. J Am Coll Cardiol. In press.
19. Altman DG, Schulz KF. Statistics notes: concealing treatment allocation in randomised trials. BMJ. 2001;323:446-447. (Pubitemid 32801405)
20. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42-46. (Pubitemid 32682008)
21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
22. Jensen LO, Thayssen P, Tilsted HH, Ravkilde J, Junker A, Hansen HS, Hansen KN, Pedersen KE, Sorensen HT, Thuesen L, Lassen JF. Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (Cypher Select+) coronary stents in unselected patients with coronary heart disease. Cardiology. 2010;116:73-78.
23. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
24. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care: Metaanalysis in Context. London: BMJ Publishing; 2001:357.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560. (Pubitemid 37088507)
27. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56:S1-S42.